Andra AP fonden Has $11.86 Million Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Key Points

• Andra AP fonden reduced its IDEXX Laboratories stake by 23.7% in the second quarter, selling 7,000 shares and retaining 22,531 shares valued at approximately $11.86 million. Institutional investors collectively own 87.84% of the company.
• IDEXX reported quarterly earnings of $4.27 per share, exceeding the $3.94 consensus estimate, while revenue rose 9.7% year over year to $1.22 billion. The company issued fiscal 2026 EPS guidance of $14.69–$14.94.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $747, compared with the stock’s reported price of $521.50; recent ratings included both target increases and cuts, alongside mostly neutral or positive views.

Andra AP fonden decreased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 23.7% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 22,531 shares of the company's stock after selling 7,000 shares during the period. Andra AP fonden's holdings in IDEXX Laboratories were worth $11,861,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of IDXX. National Pension Service increased its holdings in IDEXX Laboratories by 5.6% in the 2nd quarter. National Pension Service now owns 129,305 shares of the company's stock worth $68,071,000 after purchasing an additional 6,885 shares in the last quarter. Engineers Gate Manager LP grew its holdings in shares of IDEXX Laboratories by 162.6% during the second quarter. Engineers Gate Manager LP now owns 5,186 shares of the company's stock worth $2,730,000 after purchasing an additional 3,211 shares during the last quarter. IFP Advisors Inc grew its holdings in shares of IDEXX Laboratories by 9.8% during the second quarter. IFP Advisors Inc now owns 585 shares of the company's stock worth $308,000 after purchasing an additional 52 shares during the last quarter. Sterling Investment Advisors Ltd. increased its stake in shares of IDEXX Laboratories by 9.1% in the second quarter. Sterling Investment Advisors Ltd. now owns 1,200 shares of the company's stock valued at $632,000 after buying an additional 100 shares during the period. Finally, Arizona State Retirement System grew its stake in shares of IDEXX Laboratories by 4.9% in the second quarter. Arizona State Retirement System now owns 22,772 shares of the company's stock worth $11,988,000 after purchasing an additional 1,074 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Price Performance

IDXX opened at $521.50 on Wednesday. IDEXX Laboratories, Inc. has a 1 year low of $500.61 and a 1 year high of $769.98. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. The company has a market capitalization of $41.08 billion, a price-to-earnings ratio of 36.67, a P/E/G ratio of 2.75 and a beta of 1.54. The firm's fifty day moving average price is $549.01 and its two-hundred day moving average price is $559.31.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, topping the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The business had revenue of $1.22 billion for the quarter, compared to analysts' expectations of $1.20 billion. During the same period in the previous year, the company earned $3.50 earnings per share. The firm's revenue for the quarter was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on IDXX shares. Citigroup raised their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 5th. Weiss Ratings downgraded shares of IDEXX Laboratories from a "hold (c+)" rating to a "hold (c)" rating in a research report on Thursday, August 27th. Barclays cut their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 11th. Wall Street Zen lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th. Finally, UBS Group increased their price target on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a "neutral" rating in a report on Wednesday, August 5th. Six analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $747.00.

Insider Activity

In other news, Director Lawrence D. Kingsley sold 2,203 shares of IDEXX Laboratories stock in a transaction on Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the sale, the director directly owned 9,568 shares in the company, valued at $5,090,941.44. The trade was a 18.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.79% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops and provides diagnostic, information technology and veterinary practice-management products and services. The company primarily serves the companion animal, livestock and poultry, and water testing markets, helping customers detect, monitor and manage disease.

Its companion animal business includes in-house laboratory analyzers and consumables, reference laboratory services, diagnostic tests, veterinary software, digital imaging and related practice-management solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.